Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
August 1, 2022
Another PDL-1 drug demonstrating improved outcomes with far less toxic events. More agents in the same class are welcome additions for patient care, to drive costs down and increase options.
